Israel’s Largest Company Laying Off Half Its Israeli Workers
TEL AVIV (Reuters) – Israel-based Teva Pharmaceutical Industries will unveil a restructuring plan on Thursday that will include laying off more than half its Israeli workforce, the Calcalist financial news website said.
Teva’s plan includes closing its research and development center in the coastal city of Netanya, selling its logistics center in Shoham and cutting 3,300 jobs out of 6,430 in Israel, Calcalist said, citing people familiar with the matter.
Saddled with nearly $35 billion in debt since acquiring Allergan’s Actavis generic drug business for $40.5 billion, Teva made a series of changes after Kare Schultz joined as its new chief executive on Nov. 1.
A spokeswoman for Teva, the world’s largest generic drug maker which employs more than 56,000 people, declined to comment on Wednesday’s report, while Israeli Finance Minister Moshe Kahlon said only he was following the situation closely.
Meir Babayoff, chairman of the Negev region in the Histadrut labor federation, vowed to stop any layoffs and called on Israel’s government “to wake up,” but declined to detail what actions labor leaders plan pending an official announcement from Teva.
Teva said on Tuesday that Yitzhak Peterburg, who previously served as its chairman and interim CEO, had resigned from its board with immediate effect.
A message from our CEO & publisher Rachel Fishman Feddersen
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse..
Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.
— Rachel Fishman Feddersen, Publisher and CEO